EVALUTION OF THE MUTAGENIC EFFECT OF CIPROFLOXACIN IN THE BONE MARROW CELLS OF MICE | BIONATURE

Ciprofloxacin (Cifran) is a 4-quinolone antibiotic used to treat bacterial infections of the respiratory tract, ENT, and genitourinary tract, as well as other severe systemic infections. The possibility of it being mutagenic was studied using mouse bone marrow metaphase chromosomal studies.

The medicine was given in four distinct doses: 37.5, 75.0, 150.0, and 300.0 mg/kg body weight. A dose of 37.5 mg/kg is equivalent to a human therapeutic dose. The medicine was given as a single dose orally in a 0.2ml solution dissolved in purified water. The animals were harvested at 24-hour intervals to investigate the drug's dose yield effect. Animals given a 150.0 mg/kg dosage were euthanized at 24, 48, 72, and 96 hours to investigate the drug's time yield effect. We kept a sufficient number of distilled water negative and cyclophosphamide-treated positive control mice. Tijo and Whang's usual colchicine-hypotonic-acetic-methanol procedure was used to make bone marrow slides (1962).

Gaps, breaks, rings, exchanges, stickiness, pulverisation, fragmentation, and other chromosomal abnormalities were all graded. Gaps were the most prevalent among them. Only at the highest dose of 300 mg/kg body weight did Cifran cause substantial rates of total abnormalities. Both cifran and cyclophosphamide-treated mice showed a time-dependent decrease in aberrations. In both ciprofloxacin and cyclophosphamide-treated mice, a dose-dependent drop in the mitotic index value was found, however it was not statistically significant. The non-mutagenecity of ciprofloxacin at human therapeutic dose was discovered in this investigation.

Please see the link :- https://globalpresshub.com/index.php/BN/article/view/643